Systemic immune modulation by stereotactic radiotherapy in early-stage lung cancer.

Gkika, Eleni; Firat, Elke; Adebahr, Sonja; Graf, Erika; Popp, Ilinca; Radicioni, Gianluca; Lo, Simon S; Nestle, Ursula; Nicolay, Nils H; Niedermann, Gabriele; Duda, Dan G; Grosu, Anca-L

Gkika, Eleni; Firat, Elke; Adebahr, Sonja; Graf, Erika; Popp, Ilinca; Radicioni, Gianluca; Lo, Simon S; Nestle, Ursula; Nicolay, Nils H; Niedermann, Gabriele; Duda, Dan G; Grosu, Anca-L.

Afiliación

Gkika E; Department of Radiation Oncology, Medical Center-University of Freiburg, Faculty of Medicine, Freiburg, Germany.
Firat E; German Cancer Consortium (DKTK), Partner Site Freiburg, German Cancer Research Center, Heidelberg, Germany.
Adebahr S; Department of Radiation Oncology, Medical Center-University of Freiburg, Faculty of Medicine, Freiburg, Germany.
Graf E; German Cancer Consortium (DKTK), Partner Site Freiburg, German Cancer Research Center, Heidelberg, Germany.
Popp I; Department of Radiation Oncology, Medical Center-University of Freiburg, Faculty of Medicine, Freiburg, Germany.
Radicioni G; German Cancer Consortium (DKTK), Partner Site Freiburg, German Cancer Research Center, Heidelberg, Germany.
Lo SS; Institute of Medical Biometry and Statistics, Medical Center-University of Freiburg, Faculty of Medicine, Freiburg, Germany.
Nestle U; Department of Radiation Oncology, Medical Center-University of Freiburg, Faculty of Medicine, Freiburg, Germany.
Nicolay NH; German Cancer Consortium (DKTK), Partner Site Freiburg, German Cancer Research Center, Heidelberg, Germany.
Niedermann G; Department of Radiation Oncology, Medical Center-University of Freiburg, Faculty of Medicine, Freiburg, Germany.
Duda DG; German Cancer Consortium (DKTK), Partner Site Freiburg, German Cancer Research Center, Heidelberg, Germany.
Grosu AL; Department of Radiation Oncology, University of Washington School of Medicine, Seattle, WA, USA.

NPJ Precis Oncol ; 7(1): 24, 2023 Mar 02.

Article en En | MEDLINE | ID: mdl-36864234

RESUMEN

We performed a prospective study of circulating immune cell changes after stereotactic body radiotherapy (SBRT) in 50 early-stage NSCLC patients. We found no significant increase in CD8+ cytotoxic T lymphocytes at first follow-up (the primary endpoint) but detected a significant increase in expanding Ki-67+CD8+ and Ki-67+CD4+ T-cell fractions in patients treated with 10 Gy or less per fraction. SBRT can induce significant expansion in circulating effector T-cells immediately post-treatment.

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Tipo de estudio: Observational_studies Idioma: En Revista: NPJ Precis Oncol Año: 2023 Tipo del documento: Article País de afiliación: Alemania Pais de publicación: Reino Unido

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google